SRPT

Announcements

Nothing here yet

Daily updates

• Jefferies analysts described Sarepta Therapeutics as a potential turnaround story with catalysts extending into 2027 after updated Elevidys data showed clinically meaningful benefits in older ambulatory Duchenne muscular dystrophy patients.Oct 4, 2026

FDA designations

Nothing here yet

News

• Sarepta received FDA acceptance for sNDAs covering AMONDYS 45 and VYONDYS 53Jul 1, 2026
• Sarepta announced it will present initial clinical data from its siRNA pipeline targeting FSHD1 and DM1Mar 25, 2026
• Sarepta reported initial clinical data from its siRNA pipeline targeting FSHD1 and DM1Mar 25, 2026
• Sarepta began screening and enrollment in ENDEAVOR Cohort 8 evaluating enhanced immunosuppression with ELEVIDYS gene therapy in non-ambulant Duchenne patientsMar 16, 2026
• Sarepta Therapeutics received Clinical Trial Application approval for SRP-1005 Huntington's treatmentFeb 4, 2026